Unapproved fat-dissolving products sold online
This article was originally published in The Tan Sheet
Executive Summary
FDA sent warning letters to U.S. health spas and a Brazil-based online retailer, which operates the Web sites zipmed.net and mesoone.com, about unapproved "lipodissolve" products and procedures. Lipodissolve involves drug injections intended to dissolve and permanently remove pockets of fat. The most commonly injected substances are the lecithin phosphatidylcholine and the bile acid dioxycholate, usually together and combined with vitamins, minerals and herbal extracts. A third substance that is an approved drug to treat respiratory problems in premature infants, Forest's Infasurf (calfactant), also has been found in lipodissolve formulations, according to FDA. The agency has received reports of permanent scarring, hard lumps and dark spots on consumers' skin after lipodissolve treatments. While FDA sent a warning letter about lipodissolve to only one Web retailer, more sites likely sell the products directly to consumers, Kathleen Anderson, deputy director in the Center for Drug Evaluation and Research's Division of New Drugs and Labeling Compliance, said during an April 6 conference call
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.